The Clinical Impact of the C(0)/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients

Tacrolimus is metabolized by CYP3A4 and CYP3A5 enzymes. Patients expressing CYP3A5 (in Caucasian patients about 15% of the population but more frequent in African Americans and Asians) have a dose requirement that is around 50% higher than non-expressers to reach the target concentration. CYP3A5 exp...

Descripción completa

Detalles Bibliográficos
Autores principales: van Gelder, Teun, Meziyerh, Soufian, Swen, Jesse J., de Vries, Aiko P. J., Moes, Dirk Jan A. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411304/
https://www.ncbi.nlm.nih.gov/pubmed/32848756
http://dx.doi.org/10.3389/fphar.2020.01142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411304/
https://www.ncbi.nlm.nih.gov/pubmed/32848756
http://dx.doi.org/10.3389/fphar.2020.01142

Ejemplares similares